Hala Borno, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFFellowship Hematology/Oncology
    UCSFResidency Internal Medicine
    UNC Chapel HillDoctor of MedicineSchool of Medicine
    UNC Chapel HillBachelor of ScienceBiochemistry
    Collapse Awards and Honors
    NIA2017  - 2019T32-AG000212
    Clinical Innovation Center UCSF2017  - 2018Inside Out Accelerator
    UCSF RAP2018  - 2019Integrative Pilot Award
    Prostate Cancer Foundation2018  - 2021Young Investigator Award

    Collapse Overview 
    Collapse Overview
    Dr. Hala Borno is a medical oncologist specializing in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. She cares for patients at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Her academic interests include cancer disparities and digital health technologies that improve clinical trial participation. Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics. She is now faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology. At HDFCCC, she is a member of the cancer committee, quality council, cancer control program, and prostate program. She is also a member of the American Society of Clinical Oncology and health disparities committee for Alliance for Clinical Trials in Oncology.

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hala T. Borno; Daphne Y. Lichtensztajn; Scarlett L. Gomez; Nynikka R. Palmer; and Charles J. Ryan.Differential Use of Medical Versus Surgical Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer. CANCER. 2018; 0(0):0.
    2. Borno HT, Lichtensztajn DY, Gomez SL, Palmer NR, Ryan CJ. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer. Cancer. 2019 Feb 01; 125(3):453-462. PMID: 30444526.
      View in: PubMed
    3. Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2018 Nov 14. PMID: 30426794.
      View in: PubMed
    4. Hala T. Borno, Eric J. Small.Apalutamide and its use in the treatment of prostate cancer. Future Oncology. 2018; 0(0):0.
    5. Samuel Craig Brondfield, Hala T. Borno, Claire Mulvey, Li-Wen Huang, Pelin Cinar.Journal of Clinical Oncology. Implementation of a fellow-initiated financial toxicity screening tool in medical oncology clinics. 2018; 30_suppl(36):64-64.
    6. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. PMID: 30272035.
      View in: PubMed
    7. Atreya CE, Kubo A, Borno HT, Rosenthal B, Campanella M, Rettger JP, Joseph G, Allen IE, Venook AP, Altschuler A, Dhruva A. Being Present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers. PLoS One. 2018; 13(7):e0199423. PMID: 30036361.
      View in: PubMed
    8. Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials. Oncologist. 2018 Oct; 23(10):1242-1249. PMID: 29700209.
      View in: PubMed
    9. Hala T Borno, Joseph P. McGuire, Ann C. Griffin, Charles J. Ryan, Celia Kaplan, Eric Jay Small.Journal of Clinical Oncology. Minority Equity and Recruitment Into Trials program: Self-assessment of disease-specific cancer clinical trial recruitment patterns at a comprehensive cancer center. 2018; 36(6_suppl ):267-267.
    10. Hala T. Borno, Janet E. Cowan, Shoujun Zhao, Peter Carroll, Charles J. Ryan.CaPSURE update: Examining primary treatment and survival among men with prostate cancer and bony metastatic disease. 2018.
    11. Borno H. Blood and conflict: managing bleeding disorders in Gaza. East Mediterr Health J. 2018 Jan 02; 23(11):786-787. PMID: 29319151.
      View in: PubMed
    12. Natalini J, Borno H, Jin L, Jensen T.An unusual manifestation of diabetic ketoacidosis and acute colonic pseudo-obstruction. The Royal Society of Medicine Journals. 2017; 8(6).
    13. Borno H, Siegel A, Ryan C. The problem of representativeness of clinical trial participants: understanding the role of hidden costs. J Health Serv Res Policy. 2016 07; 21(3):145-6. PMID: 26888478.
      View in: PubMed
    14. Borno HT, Hussein EA, Dudin A, van Aalst JA. Incidence of cleft lip and palate in the palestinian territories: a retrospective study from the Makassed Hospital neonatal unit. Cleft Palate Craniofac J. 2014 Jul; 51(4):472-5. PMID: 23551076.
      View in: PubMed
    15. Hussein E, Borno HT, van Aalst JA.Cleft Lip and Palate Diagnosis and Management. Birthing and Building Nascent Cleft Teams in Developing Countries. 2012; 871-877.